Shelter Pharma Ltd

Shelter Pharma Ltd has issued a corrigendum to its earlier intimation regarding the H2 FY2026 Investor Conference Call. The correction addresses a typographical error in the day of the week for the call, which was incorrectly stated as Wednesday, June 19, 2026. The company clarified that the correct day is Friday, June 19, 2026. All other details, including the date, time, meeting link, and meeting ID, remain unchanged. Shelter Pharma Ltd regrets any inconvenience caused by this error.

Shelter Pharma Limited has announced the cancellation of its H2 FY2026 Investor Conference Call, originally scheduled for June 10, 2026. The company cited unavoidable circumstances for the withdrawal. A revised date and details for the conference call will be communicated separately in due course. The company has apologized for any inconvenience caused by this cancellation.

Shelter Pharma Ltd has successfully completed the manufacturing of an export order for Joemega Capsules, valued at USD 141,600 (approximately ₹11.7 crore), from Taha Drugs & Chemicals Co. Ltd in Sudan. The company has commenced dispatch of the order, with products worth USD 118,634 (approximately ₹9.8 crore) already shipped. The remaining balance of USD 22,966 (approximately ₹1.9 crore) is being dispatched according to the schedule. This signifies continued international business operations and revenue generation from export markets.

Shelter Pharma Limited has received the renewal of its Manufacturing Licence (Form 25D) from the Food & Drugs Control Administration (Ayurved), Government of Gujarat. The renewed licence, which covers the manufacturing and sale of Ayurvedic, Siddha, and Unani drugs at the company's Himatnagar facility, is valid until September 2030. This renewal ensures the continuity of manufacturing operations and supports the company's growth strategy within the Ayurvedic healthcare sector.

Shelter Pharma Ltd confirmed no deviation or variation in the utilization of proceeds from its Preferential Issues of Warrants convertible into Equity Shares for the half year and year ended March 31, 2026. The company raised ₹25.31 Cr (Rs. 2531.2 lakhs) through this preferential issue, which was approved in an Extraordinary General Meeting held on July 23, 2025. The entire amount was allocated and fully utilized for working capital requirements as per the approved objects. The statement of deviation, confirming no deviation, was duly reviewed by the Audit Committee and certified by the company's auditors.

The Board of Directors of 543963 (SHELTER PHARMA LIMITED) met on May 28, 2026. During the meeting, the Board approved the standalone audited financial results for the half year and year ended March 31, 2026, which included an unmodified auditor's opinion. Additionally, CA Ismail Ibrahimbhai Lakhani (M/S. I I LAKHANI & CO) was appointed as the Internal Auditor for the financial year 2026-27.

Shelter Pharma Limited's Board of Directors convened on May 28, 2026, to approve the Standalone Audited Financial Results for the half year and full year ended March 31, 2026. The results, submitted under SEBI (LODR) Regulation 33, include an Auditor's Report with an unmodified opinion. Additionally, the Board appointed CA Ismail Ibrahimbhai Lakhani (M/S. I I LAKHANI & CO) as the Internal Auditors for the financial year 2026-27. The company has enclosed the financial statements, auditor's report, and the internal auditor's brief profile.

The Board of Directors of SHELTER PHARMA LIMITED convened on May 28, 2026, approving the Standalone Audited Financial Results for the half year and full year ended March 31, 2026. The company submitted these results, accompanied by an Auditor's Report with an unmodified opinion, in compliance with SEBI (LODR) Regulations, 2015. Additionally, the Board appointed CA Ismail Ibrahimbhai Lakhani (M/S. I I LAKHANI & CO) as the Internal Auditor for the financial year 2026-27.

Shelter Pharma Ltd has scheduled a Board of Directors meeting on May 28, 2026, to consider and approve the audited financial results for the half year and year ended March 31, 2026, as per Regulation 33 of the SEBI (LODR) Regulations, 2015. The meeting will also address other agendas as deemed necessary by the chair.

Shelter Pharma Ltd. has announced that it is continuously receiving positive feedback from customers regarding its human and animal healthcare products. This feedback, shared through e-commerce portals and the company's website, highlights the effectiveness, quality, and reliability of the products. The company believes this positive response reflects its focus on research, quality standards, and customer satisfaction, which is expected to support long-term growth and brand value. Shelter Pharma considers this development material, as it strengthens the company's goodwill and business visibility in the veterinary and healthcare industry.